Managing Director in Stifel's Global Healthcare Group. Over three decades and 150+ transactions worth more than $100 billion at the center of biopharma — from Genentech's inaugural bond to Chiron's $5.1B sale to Novartis to Pfizer's largest-ever buyback. Ph.D. economist (UCLA), former finance professor at Ohio State, and co-founder of Torreya (acquired by Stifel in 2023). I write on where biopharma capital markets are heading — and who's moving them.
